We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-10.95%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.5B
AUM Growth
-$293M
Cap. Flow
-$295M
Cap. Flow %
-11.83%
Top 10 Hldgs %
36.69%
Holding
119
New
16
Increased
26
Reduced
20
Closed
21

Top Buys

Rank Stock Value
1
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$120M
2
VTRS icon
Viatris
VTRS
+$32.1M
3
VCEL icon
Vericel Corp
VCEL
+$31.5M
4
AGN
Allergan plc
AGN
+$29.5M
5
ACRS icon
Aclaris Therapeutics
ACRS
+$28.9M

Top Sells

Rank Stock Value
1
DBVT
DBV Technologies
DBVT
+$65.1M
2
ECYT
Endocyte, Inc. Common Stock
ECYT
+$62.4M
3
ACHC icon
Acadia Healthcare
ACHC
+$27.8M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$26.9M
5
RGNX icon
Regenxbio
RGNX
+$20.8M

Sector Composition

Rank Sector Weight
1 Healthcare 69.79%
2 Financials 1.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGTX icon
76
MeiraGTx Holdings
MGTX
$1.15B
$2.26M 0.09%
+234,000
New +$2.95M
AXGN icon
77
Axogen
AXGN
$2.13B
$2.14M 0.09%
+104,674
New +$3.27M
NVTR
78
DELISTED
Nuvectra Corporation Common Stock
NVTR
$2.11M 0.08%
129,000
-149,890
-54% -$2.87M
KIDS icon
79
OrthoPediatrics
KIDS
$485M
$2.03M 0.08%
58,247
– –
NEOS
80
DELISTED
Neos Therapeutics, Inc
NEOS
$2.03M 0.08%
+1,230,267
New +$3.45M
SVRA icon
81
Savara
SVRA
$1.14B
$1.89M 0.08%
250,000
– –
ALPN
82
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.75M 0.07%
475,450
-137,417
-22% -$678K
KA
83
DELISTED
Kineta, Inc. Common Stock
KA
$1.36M 0.05%
+2,993
New +$2.03M
VYGR icon
84
Voyager Therapeutics
VYGR
$189M
$1.11M 0.04%
117,647
– –
MNKD icon
85
MannKind Corp
MNKD
$1.24B
$1M 0.04%
+943,298
New +$1.6M
VTAK icon
86
Catheter Precision
VTAK
$1.79M
– –
-1
Closed -$2.36M
HYPD
87
Hyperion DeFi Inc
HYPD
$41.7M
$855K 0.03%
3,750
– –
MLNT
88
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$265K 0.01%
66,780
-395,592
-86% -$5.06M
OCGN icon
89
Ocugen
OCGN
$450M
$26K ﹤0.01%
4,935
– –
AGIO icon
90
Agios Pharmaceuticals
AGIO
$2.39B
– –
-348,200
Closed -$26.9M
ALLK
91
DELISTED
Allakos
ALLK
– –
-225,000
Closed -$10.1M
BLUE
92
DELISTED
bluebird bio
BLUE
– –
-4,743
Closed -$8.97M
DBVT
93
DBV Technologies
DBVT
$845M
– –
-290,000
Closed -$65.1M
QURE icon
94
uniQure
QURE
$2.82B
– –
-241,430
Closed -$8.79M
RGNX icon
95
Regenxbio
RGNX
$567M
– –
-275,000
Closed -$20.8M
VKTX icon
96
Viking Therapeutics
VKTX
$4.34B
– –
-460,000
Closed -$8.01M
ZBH icon
97
Zimmer Biomet
ZBH
$17.4B
– –
-124,630
Closed -$15.9M
GTHX
98
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-287,000
Closed -$15M
ALBO
99
DELISTED
Albireo Pharma Inc
ALBO
– –
-120,000
Closed -$3.96M
EPZM
100
DELISTED
Epizyme, Inc
EPZM
– –
-1,779,094
Closed -$18.9M
1 2 3
4
5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2018 Portfolio in Review

As of Q4 2018, Deerfield Management held 119 positions worth $2.5B, down 11% from $2.79B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Deerfield Management withdrew a net $295M in Q4 2018, closing 21 positions and reducing 20 holdings. Its most notable exit was DBV Technologies, an estimated $65.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 69% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Orchard Therapeutics plc American Depositary Shares worth $126M.

  • Deerfield Management's largest Q4 2018 buy was Orchard Therapeutics plc American Depositary Shares: 802,360 shares worth $126M.
  • Deerfield Management added most to Viatris in Q4 2018, an estimated $32.1M increase.
  • Deerfield Management's biggest Q4 2018 reduction was Acadia Healthcare, cutting an estimated $27.8M.
  • Deerfield Management fully exited DBV Technologies in Q4 2018, selling an estimated $65.1M.
  • Deerfield Management's ten largest holdings make up 37% of its $2.5B portfolio in Q4 2018.
  • Deerfield Management opened 16 new positions and closed 21 in Q4 2018.
  • Deerfield Management's portfolio value fell 11% quarter-over-quarter to $2.5B.

Based on Deerfield Management's 13F filing for Q4 2018, filed 14 Feb 2019.